Sepsis: Diagnostic and Therapeutic Challenges

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Molnár, Zsolt ^a   Giamarellos Bourboulis, Evangelos J ^b   Kumar, Anand ^c   Nierhaus, Axel ^d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ANTISEPSIS; ARTIFICIAL VENTILATION; COLORECTAL CANCER; CRITICALLY ILL PATIENT; EDITORIAL; FEVER; HEMODYNAMICS; HUMAN; INTENSIVE CARE; LEUKOCYTOSIS; MULTICENTER STUDY (TOPIC); OXYGEN THERAPY; RENAL REPLACEMENT THERAPY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; MULTIPLE ORGAN FAILURE; PROCEDURES; TREATMENT OUTCOME;

CRITICAL CARE; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS; TREATMENT OUTCOME;

EID: 84994593690     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/5786182     Document Type: Editorial

References (12)

1. K.-M. Kaukonen, M. Bailey, S. Suzuki, D. Pilcher, R. Bellomo, "Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012, " Journal of the American Medical Association, vol. 311, no. 13, pp. 1308-1316, 2014.
2. D. F. Gaieski, J. M. Edwards, M. J. Kallan, B. G. Carr, "Benchmarking the incidence and mortality of severe sepsis in the united states, " Critical CareMedicine, vol. 41, no. 5, pp. 1167-1174, 2013.
3. C. M. Torio and R. M. Andrews, "National Inpatient Hospital Costs:TheMost Expensive Conditions by Payer, 2011: Statistical Brief #160, " Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Health Care Policy and Research, Rockville, Md, USA, 2006-2013.
4. S. Heublein, M. Hartmann, S. Hagel, R. Hutagalung, F. M. Brunkhorst, "Epidemiology of sepsis in German hospitals derived from administrative databases, " Infection, vol. 17, article S71, 2013.
5. C. Engel, F. M. Brunkhorst, H.-G. Bone et al., "Epidemiology of sepsis in Germany: results from a national prospective multicenter study, " Intensive Care Medicine, vol. 33, no. 4, pp. 606-618, 2007.
6. I. László, D. Trásy, Z. Molnár, J. Fazakas, "Sepsis: frompathophysiology to individualized patient care, " Journal of Immunology Research, vol. 2015, Article ID 510436, 13 pages, 2015.
7. R. C. Bone, C. J. Fisher Jr., T. P. Clemmer, G. J. Slotman, G. A. Metz, R. A. Balk, "Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group, " Critical Care Medicine, vol. 17, no. 5, pp. 389-393, 1989.
8. M. Singer, C. S. Deutschman, C. W. Seymour et al., "The third international consensus definitions for sepsis and septic shock (Sepsis-3), " Journal of the American Medical Association, vol. 315, no. 8, pp. 801-810, 2016.
9. J.-L. Vincent, "We should abandon randomized controlled trials in the intensive care unit, " Critical CareMedicine, vol. 38, no. 10, pp. S534-S538, 2010.
10. A. Kumar, D. Roberts, K. E. Wood et al., "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, " Critical Care Medicine, vol. 34, no. 6, pp. 1589-1596, 2006.
11. R. S. Hotchkiss, G. Monneret, D. Payen, "Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach, "TheLancet InfectiousDiseases, vol. 13, no. 3, pp. 260-268, 2013.
12. G. Monneret and F. Venet, "Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy, " Cytometry Part B: Clinical Cytometry, vol. 90, no. 4, pp. 376-386, 2016.